On Invalid Date, Organon & Co (NYSE: OGN) reported Q4 2023 earnings per share (EPS) of $2.14, up 409.52% year over year. Total Organon & Co earnings for the quarter were $546.00 million. In the same quarter last year, Organon & Co's earnings per share (EPS) was $0.42.
As of Q2 2024, Organon & Co's earnings has grown 11.08% year over year. This is 15.77 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of -4.69%. Organon & Co's earnings in the past year totalled $1.02 billion.
What is OGN's earnings date?
Organon & Co's earnings date is Invalid Date. Add OGN to your watchlist to be reminded of OGN's next earnings announcement.
What was OGN's revenue last quarter?
On Invalid Date, Organon & Co (NYSE: OGN) reported Q4 2023 revenue of $1.60 billion up 7.61% year over year. In the same quarter last year, Organon & Co's revenue was $1.49 billion.
What was OGN's revenue growth in the past year?
As of Q2 2024, Organon & Co's revenue has grown 1.44% year over year. This is 3.75 percentage points lower than the US Drug Manufacturers - General industry revenue growth rate of 5.19%. Organon & Co's revenue in the past year totalled $6.26 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.